A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females at least 18 years of age who have confirmed diagnosis of Non-small Cell Lung Cancer
Patients with no systemic prior systemic treatment for lung cancer except patients at least 12 months from prior adjuvant therapy
Adequate bone marrow,kidney and liver function
Must be recovered and at least 4 weeks from major surgery or radiation
ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1
Men and women must agree to use birth control during the study
Women able to have children must have a negative pregnancy test 14 days before study enrollment
You may not be if
Patients with prior treatment with other investigational agents less than 4 weeks before study enrollment
Pregnant or nursing female patients
Patients who are HIV positive
Patients who have Hepatitis A, B, or C
Patients unable to take study medication by mouth
Patients with untreated brain cancer
Patient eligible for treatment with bevacizumab and for whom bevacizumab is available
Clareo Health | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
